The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1265
July 16, 2007
View Complete Issue         Table of Contents 2019 
Lisdexamfetamine dimesylate (Vyvanse) for ADHD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lisdexamfetamine dimesylate (Vyvanse) for ADHD
July 16, 2007 (Issue: 1265)
Lisdexamfetamine dimesylate (Vyvanse - Shire), a prodrug in which d-amphetamine is covalently bonded to L-lysine, has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-12 years old. It was...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lisdexamfetamine dimesylate (Vyvanse) for ADHD
Article code: 1265b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.